3E Bioventures Capital is a healthcare-focused venture capital firm that invests in global health innovators, specifically targeting innovative therapeutic drugs and disruptive cross-disciplinary med-tech in medical devices and diagnostics. Their strategy is science-driven and entrepreneur-friendly, focusing on early and growth-stage companies in Biotech and TechBio to address unmet medical needs.
75% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals). Average disclosed round size is $45.9M (across 7 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 OncoC4 | Series B | — | Oct 2025 |
| AArnatar Therapeutics | Series A | $52M | Dec 2024 |
 Smartlens, Inc. | Series A | $6.1M | Jul 2023 |
 Lipidio Pharmaceuticals Inc. | Series A | $20M | Nov 2022 |
 Dewpoint Therapeutics | Series C | $150M | Feb 2022 |
 Subtle Medical | Series A | $12.2M | Nov 2020 |
 OncoImmune, Inc. | Series B | $56M | Sep 2020 |
 Refuge Biotechnologies, Inc. | Series B | $25M | May 2018 |
Top Co-Investors
HMI Capital2 shared
Stanford University1 shared
Graphene Ventures1 shared
Boutique Venture Partners1 shared
Wilson Sonsini1 shared
Sequoia China1 shared
Danhua Capital1 shared
WuXi Healthcare Ventures1 shared
ShangBay Capital1 shared
SoftBank Vision Fund1 shared
General Catalyst1 shared
Mubadala Ventures1 shared
Mirae Asset1 shared
NS Investment1 shared
Leaps by Bayer1 shared
Polaris Venture Partners1 shared
Samsara BioCapital1 shared
ARCH Venture Partners1 shared
Maverick Ventures1 shared
Eight Roads Ventures1 shared
Last updated: 21 April 2026